Project Grant K99HL175104
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $540,856 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) on Dec 15, 2024. The goal of this 4-year project is to identify transcriptional regulators that control endocardial-specific gene expression and valve development, as well as understand the regulation and function of the SLC16A2 gene during heart injury and regeneration. The...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $134,998 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the J. David Gladstone Institutes in San Francisco, CA. The grant, awarded on July 20, 2025, will support research to define the cellular and molecular mechanisms driving the formation of the linear heart tube during embryonic development. The primary objectives are to: 1) quantitatively analyze cell movements and behaviors required for proper...
- This $761,152 project grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of California, San Diego (UCSD) to investigate the gene regulatory mechanisms controlling the expression of cardiac myosin heavy chain proteins. The goal is to understand how shifts in the ratio of the MYH6 and MYH7 isoforms impact cardiac contractility, which is critical for heart function under both normal and disease...
- This $568,177 federal Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on how centrioles, the core structures of centrosomes, control mammalian development. The University of California, San Francisco (UCSF) is the primary awardee and will leverage advanced techniques like centrosome affinity capture mass spectrometry and pan-expansion microscopy to investigate how centriole defects...
- The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
- The federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $865,286 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to develop a high-resolution spatiotemporal lineage map of cardiac development. The research aims to spatiotemporally map early cardiac progenitor lineages and their clonal relationships, map the phylogeny of major myocardial cell...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1 to the Regents of the University of California, San Francisco (UCSF) to explore the changing patterns of cardiac calcium signaling during embryonic heart development. The research aims to define the precise rules governing how cellular calcium dynamics map to downstream developmental processes, in order to better understand the mechanisms underlying a...
- This Project Grant award of $706,519 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the regulatory role of the NIPBL gene in human cardiac cells. The grant recipient, the University of Pittsburgh, is using an inducible NIPBL depletion human induced pluripotent stem cell model to study NIPBL's function as a transcription regulator in cardiomyocytes. The research aims to elucidate the mechanisms by which NIPBL...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate how signaling pathways regulate cardiac progenitor cell proliferation and lineage specification during prenatal heart development. The $439,065 award to Swarthmore College will fund a 3-year project leveraging the simplified cellular model of the marine invertebrate Ciona robusta to decipher conserved mechanisms of signal-dependent...
- This $590,283 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop feedback-controlled closed-loop manufacturing processes for differentiating human pluripotent stem cells into cardiomyocytes. The key objectives are to: 1) Identify failure modes in 2D cardiomyocyte differentiation through integrated single-cell transcriptomics and epigenomics, and 2) Develop control strategies to enhance the reproducibility of human...
This Project Grant award, valued at $150,876.00, was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Regents of the University of California, doing business as the University of California, Berkeley. The award supports research to elucidate how bone morphogenetic protein (BMP) signaling regulates the development and differentiation of cardiac neural crest cells, which are critical for proper heart formation. The study will leverage in vivo chick and mouse embryo models as well as human embryonic stem cell-based in vitro systems to define the role of the BMP signaling antagonist Noggin in establishing cardiac neural crest cell identity and contributions to heart organogenesis. The project aims to provide fundamental scientific insights into the gene regulatory mechanisms governing cardiac neural crest development, which is crucial for understanding and potentially treating congenital heart defects.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $150.9k | 7/28/25 |